EMBARGOED FOR RELEASE UNTIL 4:00 P.M. ET, WEDNESDAY, DECEMBER 10, 2025
Highlights:
GLP-1 drugs show a potential link to reduced epilepsy risk in people with type 2 diabetes.
People taking GLP-1 drugs were 16% less likely to develop epilepsy than those on DPP-4 inhibitors.
Semaglutide showed the strongest association with lower epilepsy risk among the GLP-1 drugs studied.
The study is preliminary and does not prove causation; randomized, controlled trials are needed to confirm these findings.
The drug tirzepatide was not included as it was introduced during the study period.
MINNEAPOLIS — A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published on December 10, 2025, in Neurology®, the medical journal of the American Academy of Neurology. Glucagon-like peptide-1 receptor agonists, or GLP-1 drugs, have been used for diabetes and weight loss.
The study does not prove that GLP-1 drugs lower the risk of developing epilepsy; it only shows an association.
“Additional randomized, controlled trials that follow people over time are needed to confirm these findings, but these results are promising, since people with diabetes are at increased risk for developing epilepsy later in life,” said study author Edy Kornelius, MD, PhD, of Chung Shan Medical University in Taichung, Taiwan. “Epilepsy can have many physical, psychological and social consequences, and many people do not respond to the current medications, so finding ways to reduce this risk is critical.”
For the study, researchers examined a U.S. health database for adults with type 2 diabetes who started taking either a GLP-1 drug or another type of drug called dipeptidyl peptidase-4 inhibitor (known as DPP-4 inhibitors or gliptins). None of the people had a previous diagnosis of epilepsy or seizure. The GLP-1 drugs included in the study were dulaglutide, liraglutide and semaglutide.
The 452,766 participants had an average age of 61. Half took the GLP-1 drugs and half took the DPP-4 inhibitors. They were followed for at least five years. During that time, 1,670 people taking the GLP-1 drugs developed epilepsy, or 2.35%, compared to 1,886 people taking the DPP-4 inhibitors, or 2.41%.
Once researchers adjusted for other factors that could affect the risk of epilepsy, such as age, high blood pressure and cardiovascular disease, they found that people taking the GLP-1 drugs were 16% less likely to develop epilepsy than people taking the DPP-4 inhibitors.
When researchers looked at the individual drugs, they found that the association with a lower risk of epilepsy was strongest with the drug semaglutide.
“More research is needed, but these findings support the theory that GLP-1 drugs may have neurological benefits beyond controlling blood sugar,” Kornelius said. “It should be noted that these findings do not imply that DPP-4 inhibitors are harmful in any way or that GLP-1 drugs are definitely beneficial for brain health.”
Kornelius said that tirzepatide, a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, was not included in the study, as it was introduced after the study period had started. Therefore, the findings may not apply to tirzepatide.
In addition to the limitations of the retrospective, observational design of the study, the study has other limitations. Researchers did not have information on other factors that could affect the risk of epilepsy, such as family history, genetic susceptibility or alcohol use. It’s also possible that other factors such as cost, insurance restrictions or how severe the person’s diabetes was could affect which drug they were prescribed, which could lead to differences between the two groups.
The study was supported by Chung Shan Medical University Hospital.
Discover more about epilepsy at Brain & Life®, from the American Academy of Neurology. This resource also offers a website, podcast, and books that connect patients, caregivers and anyone interested in brain health with the most trusted information, straight from the world’s leading experts in brain health. Follow Brain & Life® on Facebook, X, and Instagram.
The American Academy of Neurology is the leading voice in brain health. As the world’s largest association of neurologists and neuroscience professionals with more than 40,000 members, the AAN provides access to the latest news, science and research affecting neurology for patients, caregivers, physicians and professionals alike. The AAN’s mission is to enhance member career fulfillment and promote brain health for all. A neurologist is a doctor who specializes in the diagnosis, care and treatment of brain, spinal cord and nervous system diseases such as Alzheimer's disease, stroke, concussion, epilepsy, Parkinson's disease, multiple sclerosis, headache and migraine.
Explore the latest in neurological disease and brain health, from the minds at the AAN at AAN.com or find us on Facebook, X, Instagram, LinkedIn, and YouTube.
END
Could GLP-1 drugs affect risk of epilepsy for people with diabetes?
2025-12-10
(Press-News.org)
ELSE PRESS RELEASES FROM THIS DATE:
New circoviruses discovered in pilot whales and orcas from the North Atlantic
2025-12-10
A collaborative team of researchers (that includes students and senior researchers at Arizona State University (ASU), Coastal Carolina University, The University of the South in the US and researchers in Saint Vincent and the Grenadines, The University of the West Indies at Cave Hill (Barbados), University of Cape Town (South Africa), Institut Pasteur (France) have identified two previously unknown circoviruses in short-finned pilot whales and orcas from the Caribbean region of the North Atlantic Ocean. The findings represent the first detection of cetacean circoviruses in this region and ...
Study finds increase in risk of binge drinking among 12th graders who use 2 or more cannabis products
2025-12-10
BUFFALO, N.Y. – The cannabis marketplace continues to grow and evolve, offering consumers new ways to use cannabis — and new ways to combine it with other substances, such as alcohol. That practice can be particularly detrimental to adolescents, who are known to use both substances in high numbers.
And when it comes to cannabis use and binge drinking among high school seniors, modality matters, according to new research from the University at Buffalo finding that differing modes of cannabis consumption may be associated with risky alcohol use behaviors in this population.
The study is among the first to evaluate modes of cannabis use on binge drinking outcomes ...
New paper-based technology could transform cancer drug testing
2025-12-10
Researchers at New York University Abu Dhabi (NYUAD) have developed Spheromatrix, a simple and low-cost technology that enables tumor models to be grown, frozen, and stored for future use in cancer drug testing.
Spheromatrix is made from specially engineered filter paper patterned to support the growth of tumor spheroids in a controlled, reproducible manner. Unlike conventional approaches, which are expensive, complex, and cannot be preserved, this platform enables researchers to build biobanks of ...
Opioids: clarifying the concept of safe supply to save lives
2025-12-10
Canadian researchers want to clarify the concepts related to safe opioid supply to better assess their impact and guide public-health policies.
In Canada, thousands of people use contaminated street opioids. To reduce overdoses, the country has been experimenting for the past 10 years with the distribution of pharmaceutical opioids as an alternative to illicit drugs.
This method is often referred to as “safe supply” or “safer supply.”
What exactly do these terms, which emerged in the late 2010s and are central to Canadian harm reduction policies, mean?
In a study published in the International Journal of Drug Policy, ...
New species of tiny pumpkin toadlet discovered in Brazil highlights need for conservation in the mountain forests of Serra do Quiriri
2025-12-10
New species of tiny pumpkin toadlet discovered in Brazil highlights need for conservation in the mountain forests of Serra do Quiriri
Article URL: https://plos.io/48orUxO
Article title: A new species of Brachycephalus (Anura: Brachycephalidae) from Serra do Quiriri, northeastern Santa Catarina state, southern Brazil, with a review of the diagnosis among species of the B. pernix group and proposed conservation measures
Author countries: Brazil, U.S., Germany
Funding: The field work was funded by Fundação ...
Reciprocity matters--people were more supportive of climate policies in their country if they believed other countries were making significant efforts themselves
2025-12-10
Reciprocity matters--people were more supportive of climate policies in their country if they believed other countries were making significant efforts themselves, per survey of 4,000 Chinese, Indian, Japanese and US citizens.
Article URL: https://plos.io/4pfhbgj
Article Title: They reduce, we reduce: Perception of other countries’ climate effort predicts support for climate policies
Author Countries: China, Japan, Sweden
Funding: The work described in this study was supported by grants awarded to Kim-Pong Tam from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. 16601122 ...
Stanford Medicine study shows why mRNA-based COVID-19 vaccines can cause myocarditis
2025-12-10
Stanford Medicine investigators have unearthed the biological process by which mRNA-based vaccines for COVID-19 can cause heart damage in some young men and adolescents — and they’ve shown a possible route to reducing its likelihood.
Using advanced but now common lab technologies, along with published data from vaccinated individuals, the researchers identified a two-step sequence in which these vaccines activate a certain type of immune cell, in turn riling up another type of immune cell. The resulting inflammatory activity directly injures heart muscle cells, while triggering further ...
Biobanking opens new windows into human evolution
2025-12-10
Nijmegen, 10 December 2025 - More than a decade after the first Neanderthal genome was sequenced, scientists are still working to understand how human-specific DNA changes shaped our evolution. A new study by the Max Planck Institute for Psycholinguistics, published in Science Advances, offers an innovative approach: by scanning DNA of hundreds of thousands of people in a population biobank, researchers can identify individuals who carry the very rare archaic versions of these genetic changes, making it possible to directly observe their real-world effects in living humans.
It’s just over a decade since scientists first reported successfully sequencing the virtually ...
Sky-high smoke
2025-12-10
Key takeaways
Harvard atmospheric scientists directly sampled 5-day old wildfire smoke in the upper troposphere and found large particles that are not reflected in current climate models.
The large particles had a measurable cooling effect, with potential implications for future climate predictions
Some wildfires are so intense, they create their own weather – thunderstorms driven by heat that hurtle smoke as high as 10 miles into the sky like giant chimneys.
When these smoke plumes reach the thin, calm air of the upper troposphere and lower stratosphere, they can persist for weeks or even months – yet their ...
AI tips off scientists to new drug target to fight, treat mpox
2025-12-10
With the help of artificial intelligence, an international team of researchers has made the first major inroad to date towards a new and more effective way to fight the monkeypox virus (MPXV), which causes a painful and sometimes deadly disease that can be especially dangerous for children, pregnant women and immunocompromised people. Reporting in the journal Science Translational Medicine, the team found that when mice were injected with a viral surface protein recommended by AI, the animals produced antibodies that neutralized MPXV, suggesting the breakthrough could be used in a new mpox vaccine or antibody ...